ChemicalBook >  製品カタログ >  API >  抗腫瘍性の >  抗悪性腫瘍の天然の供給源 >  パクリタキセル


パクリタキセル 化学構造式
  • CAS番号.33069-62-4
  • 化学名:パクリタキセル
  • 别名:パクリタキセル;タキソール;パクリタキセル (JAN)
  • 英語化学名:Paclitaxel
  • 英語别名:TAXOL;taxal;CL183;EMPAC;Onxal;TAXUS;Capxol;NK 105;itaxeL;taxol a
  • CBNumber:CB3273425
  • Molecular Formula:C47H51NO14
  • Formula Weight:853.92
  • MOL File:33069-62-4.mol
パクリタキセル 物理性質
  • 融点  :213 °C (dec.)(lit.)
  • 比旋光度  :D20 -49° (methanol)
  • 沸点  :774.66°C (rough estimate)
  • 比重(密度)  :0.200
  • 屈折率  :-49 ° (C=1, MeOH)
  • 闪点  :9℃
  • 貯蔵温度  :2-8°C
  • 溶解性 :methanol: 50 mg/mL, clear, colorless
  • 外見  :powder
  • 酸解離定数(Pka) :11.90±0.20(Predicted)
  • 色 :white
  • 水溶解度  :0.3mg/L(37 ºC)
  • 極大吸収波長 (λmax) :227nm(MeOH)(lit.)
  • Merck  :14,6982
  • BRN  :1420457
  • 安定性: :Stable. Incompatible with strong oxidizing agents. Combustible.
  • CAS データベース :33069-62-4(CAS DataBase Reference)
  • EPAの化学物質情報 :Paclitaxel (33069-62-4)
  • 絵表示(GHS)
  • 注意喚起語Danger
  • 危険有害性情報
  • H225:引火性の高い液体および蒸気
  • H302:飲み込むと有害
  • H312:皮膚に接触すると有害
  • H315:皮膚刺激
  • H317:アレルギー性皮膚反応を起こすおそれ
  • H318:重篤な眼の損傷
  • H332:吸入すると有害
  • H334:吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ
  • H335:呼吸器への刺激のおそれ
  • H341:遺伝性疾患のおそれの疑い
  • H360:生殖能または胎児への悪影響のおそれ
  • H361:生殖能または胎児への悪影響のおそれの疑い
  • H370:臓器の障害
  • H371:臓器の障害のおそれ
  • H413:長期的影響により水生生物に有害のおそれ
  • 注意書き
  • P201:使用前に取扱説明書を入手すること。
  • P210:熱/火花/裸火/高温のもののような着火源から遠ざ けること。-禁煙。
  • P260:粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。
  • P261:粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。
  • P280:保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。
  • P284:呼吸用保護具を着用すること。
  • P301+P310:飲み込んだ場合:直ちに医師に連絡すること。
  • P304+P340:吸入した場合:空気の新鮮な場所に移し、呼吸しやすい 姿勢で休息させること。
  • P305+P351+P338:眼に入った場合:水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。
  • P308+P313:暴露または暴露の懸念がある場合:医師の診断/手当てを 受けること。
  • P311:医師に連絡すること。
  • P342+P311:呼吸に関する症状が出た場合:医師に連絡すること。
  • P405:施錠して保管すること。
パクリタキセル 価格 もっと(45)
  • メーカー: 富士フイルム和光純薬株式会社(wako)
  • 製品番号: W01CAY10461
  • 製品説明 : 
  • 純度: Paclitaxel
  • 包装: 5mg
  • 価格: ¥5800
  • 更新時間: 2021/03/23
  • 購入: 購入
  • メーカー: 富士フイルム和光純薬株式会社(wako)
  • 製品番号: W01CAY10461
  • 製品説明 : 
  • 純度: Paclitaxel
  • 包装: 25mg
  • 価格: ¥12900
  • 更新時間: 2021/03/23
  • 購入: 購入
  • メーカー: 東京化成工業
  • 製品番号: P1632
  • 製品説明 : パクリタキセル
  • 純度: Paclitaxel >98.0%(HPLC)
  • 包装: 100mg
  • 価格: ¥47100
  • 更新時間: 2021/03/23
  • 購入: 購入
  • メーカー: 関東化学株式会社(KANTO)
  • 製品番号: 32842-1A
  • 製品説明 : パクリタキセル
  • 純度: Paclitaxel>99.0%
  • 包装: 1mg
  • 価格: ¥8400
  • 更新時間: 2021/03/23
  • 購入: 購入
  • メーカー: 関東化学株式会社(KANTO)
  • 製品番号: 49868-89
  • 製品説明 : パクリタキセル
  • 純度: Paclitaxel
  • 包装: 10mg
  • 価格: ¥44000
  • 更新時間: 2021/03/23
  • 購入: 購入

パクリタキセル MSDS


Paclitaxel 化学特性,用途語,生産方法

  • 外観 白色~ごくうすい褐色、結晶~粉末
  • 溶解性 メタノール溶状:試験適合アセトニトリル及びメタノールにやや溶けやすく、エタノール(99.5)に溶けにくく、水にほとんど溶けない。
  • 用途 パクリタキセルは肺がん、卵巣がん、乳がん、頭頸部がん、進行性カポジ肉腫患者の治療に用いられている。また再狭窄の予防にも用いられている。 パクリタキセルは微小管を安定化させることで微小管のダイナミクスを抑制し、その結果正常な細胞分裂の進行を妨げる。ドセタキセルと共に医薬品分類のタキサン類を構成する。フロリダ州立大学のロバート?ホルトンによって初めて全合成された。
  • 用途 タキソイド系化合物です。β - チューブリンへ結合して微小管を安定化さ せ、微小管ダイナミクスを抑制することによ り有糸分裂阻害作用を示します。
  • 効能 抗悪性腫瘍薬, 微小管脱重合阻害薬
  • 商品名 アブラキサン (大鵬薬品工業); タキソール (ブリストル・マイヤーズスクイブ)
  • 説明 Paclitaxel, a natural product isolated from the bark of the Pacific yew, is effective in treating refractory metastatic ovarian cancer. Unlike any other antineoplastic agents, paclitaxel appears to have several possible mechanisms of action, including an antimicrotubule action through the promotion of tubulin polymerization and stabilization of microtubules, thereby, halting mitosis and promoting cell death. The supply of paclitaxel is limited by its low natural abundance and currently it is being manufactured by a semi-synthetic route from deacetylbaccatin Ⅲ that is isolated from the needles of the yew tree. Recent completion of two total syntheses of taxol conquered the structural complexity of the title compound and may be useful in obtaining certain closely related analogs, some of which have been found to have antitumor activity. Paclitaxel has potential uses in the treatment of metastatic breast cancer, lung cancer, head and neck cancer, and malignant melanoma.
  • 化学的特性 White Powder
  • Originator NIH (U.S.A.)
  • 使用 glucocorticoid, antiinflammatory
  • 使用 An antineoplastic. Used in the study of structure and function of microtubles into tubulin. Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanc ed forms of Kaposi's sarcoma. Paclitaxel is a mitotic inhibitor used in cancer chemotherapy.
  • 使用 Tool in study of structure and function of microtubules.
  • 適応症 Paclitaxel (Taxol) is a highly complex, organic compound isolated from the bark of the Pacific yew tree. It binds to tubulin dimers and microtubulin filaments, promoting the assembly of filaments and preventing their depolymerization. This increase in the stability of microfilaments results in disruption of mitosis and cytotoxicity and disrupts other normal microtubular functions, such as axonal transport in nerve fibers. The major mechanism of resistance that has been identified for paclitaxel is transport out of tumor cells, which leads to decreased intracellular drug accumulation. This form of resistance is mediated by the multidrug transporter P-glycoprotein.
  • Manufacturing Process (2R,3S)-β-Phenyl-isoserine methyl ester (4.35 g, 22 mM) is dissolved in dry THF (100 ml) and the flask cooled to 0°C. To the mixture is added t-butyl isocyanate (2.8 ml, 25 mM). TLC after 15 min shows some starting material left so additional isocyanate (0.5 ml) is added. TLC after 1 h shows no starting material so the solvent is concentrated under reduced pressure to give the N(t-butylaminocarbonyl)-β-phenyl isoserine methyl ester.
    Triethylamine (4.8 ml, 34.4 mmol) is added to a stirred solution of methyl (2R,3S)-phenylisoserinate (7.26 g, 31.3 mmol) in methylene chloride (80 ml) at 0°C. To this slurry of is added trimethylsilyl chloride (4.4 ml, 34.7 mmol). Additional methylene chloride (45 ml) is added. The mixture is cooled to 65°C and triethylamine (9.8 ml, 70.3 mmol) is added. p-Nitrophenylsulfonyl chloride (6.93 g, 31.3 mmol) is added. The reaction rate is too slow at -65°C so the temperature is gradually raised to 0°C. Hydrogen fluoride (10% aqueous, 5 equivalents) is added. The aqueous phase is separated from the organic (methylene chloride) phase and methanol is added to the organic phase. The methylene chloride is removed under reduced pressure and the methyl (2R,3S)-3-(4-nitrobenzenesulfonamido)-3-phenyl-2-hydroxypropionate is obtained, melting point 187-189°C.
    Benzaldehyde dimethylacetal (200 μl, 1.33 mmol) and a catalytic amount of p-toluenesulfonic acid (37 mg) are added to methyl (2R,3S)-3-(4nitrobenzenesulfonamido)-3-phenyl-2-hydroxypropionate (315 mg, 0.83 mmol) in toluene 5 ml. The mixture is heated at 100°C under reduced pressure (15 mm mercury) with no condenser. After 1 h the crude reaction mixture is diluted with ethyl acetate and washed with water (2 times). After drying the organic layer over magnesium sulfate the crude material is purified by column chormatography (silica gel; eluting with ethyl acetate/cyclohexane, 35/65) to give the (2S,4S,5R)-2,4-diphenyl-3-(4-nitrobenzenesulfonamido)-5methoxycarbonyl-1,3-oxazolidine, melting point 118°-120°C.
    Water (8 ml), methanol (8 ml) and THF (8 ml) are added to (2S,4S,5R)-2,4diphenyl-3-(4-nitrobenzenesulfonamido)-5-methoxycarbonyl-1,3-oxazolidine (1.50 g, 3.19 mmol). Potassium carbonate (1.018 g, 7.71 mmol) is then added. The resulting mixture is stirred at 20°-25°C until complete by TLC. After 5 h the reaction is complete and the reaction mixture is extracted with basic methylene chloride (2 times). The aqueous phase is then acidified with hydrochloric acid and extracted with ethyl acetate. The ethyl acetate phase is then washed with water, saline and dried over magnesiuim sulfate. Concentration of the organic phase (ethyl acetate) gives the (2S,4S,5R)-2,4diphenyl-3-(4-nitrobenzenesulfonamido)-5-carboxy-1,3-oxazolidine, melting point 61°-65°C.
    Then the (2S,4S,5R)-2,4-diphenyl-3-(4-nitrobenzenesulfonamido)-5-carboxy1,3-oxazolidine react with the 7-SDMS Baccatin III, that is 7-(3-methylbut-2yl)dimethylsilyl baccatin III (Baccatin III: 7,11-methano-1H-cyclodeca(3,4) benz(1,2-b)oxet-5-one,6,12b-bis(acetyloxy)-12(benzoyloxy)-1,2a,3,4,4a,6, 9,10,11,12,12a,12b-dodecahydro-4,9,11-trihydroxy-4a,8,13,13-tetramethyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS), isolated from Taxus baccata).
    (2S,4S,5R)-2,4-Diphenyl-3-(4-nitrobenzenesulfonamido)-5-carboxy-1,3oxazolidine(323 mg, 0.711 mmol) is mixed with toluene (2.5 ml) at 20°-25°C. Dicyclohexylcarbodiimide (160 mg, 0.775 mmol) is then added to the reaction mixture. 7-SDMS Baccatin III (156 mg, 0.218 mmol) is added followed by 4(dimethylamino)pyridine (35 mg, 0.286 mmol) and the reaction mixture is stirred at 20°-25°C until complete (1 h) by TLC. Sodium bicarbonate (50% aqueous, 10 ml) and more toluene (5 ml) is added to the reaction mixture and then stirred at 20°-25°C for 2 h. The reaction mixture is filtered through a medium frit to remove the urea byproduct. After filtering the phases are separated and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with aqueous sodium bicarbonate (50%), water and saline. The organic phases are dried over magnesium sulfate, filtered and then concentrated. The concentrate is purified by column chromatograpy (silica gel; eluting with ethyl acetate/cyclohexane, 20/80) to give the 7-SDMS baccatin III 13-(2R,4S,5R)- and (2S,4S,5R)-2,4-diphenyl-3(4-nitrobenzenesulfonamido)-1,3-oxazolidine-5-carboxylic acid ester.
    THF (13.5 ml) and DMF (1.5 ml) are cooled to -35°C and degased by alternating reduced pressure and nitrogen three times. Thiophenol (0.22 ml, 2.14 mmol) is added followed by potassium butoxide/THF (1.978 M, 0.7 ml, 1.38 mmol). After 5 min, 7-SDMS baccatin III 13-(2R,4S,5R)- and (2S,4S,5R)-2,4-diphenyl-3-(4-nitrobenzenesulfonamido)-1,3-oxazolidine-5carboxylic acid ester (877 mg, 0.762 mmol) is added. After the solids are added, the reaction mixture is slowly warmed to -10°C. The mixture is stirred at -10°C until the red color fades to yellow. After 3 h the bath is dropped allowing the mixture to warm to 20-25°C. At 20°-25°C the reaction is stirred for 1 h before assaying by TLC and HPLC. Sodium bisulfite (241 mg, 2.31 mmol) is added in water (5 ml). The mixture is stirred at 20°-25°C and after approximately 115 h the reaction is complete (by TLC) giving the free amine 7-SDMS Sodium bicarbonate (485 mg, 5.77 mmol) and water (10 ml) are added to 7SDMS baccatin III 13-(2R,3S)-3-amino-3-phenyl-2-hydroxypropionate. The mixture is cooled to 0°C and then benzoyl chloride (150 ml, 1.3 mmol) is added. After 1 hr the reaction is complete and the reaction mixture is diluted with water and extracted with ethyl acetate. The organic phases are combined and washed with water, saline and dried over magnesium sulfate. Chromatography of the crude product (silica gel column; 20% to 100% ethyl acetate gives the 7-SDMS baccatin III 13-(2R,3S)-3-benzamido-3-phenyl-2hydroxypropionate. 7-SDMS Baccatin III 13-(2R,3S)-3-benzamido-3-phenyl-2-hydroxypropionate (126 mg, 0.128 mmol) is dissolved in acetonitrile (2.5 ml). Triethylamine trihydrofluoride (123 mg, 0.763 mmol) is added under nitrogen and the resulting mixture is stirred at 5°C until complete by HPLC. When complete, the mixture is extracted with methyl t-butylether and washed with sodium bicarbonate solution. The aquesous washes are back extracted and combined with the organic phase. The combined organic phases are washed with water and saline, dried over magnesium sulfate, filtered and concentrated to give the Taxol (Paclitaxel), as needle from methanol with melting point 213-216°C.

    III 13-(2R,3S)-3-amino-3-phenyl-2-hydroxypropionate
  • brand name Abraxane (Abraxis); Taxol (Bristol-Myers Squibb).
  • Therapeutic Function Antineoplastic
  • 一般的な説明 Paclitaxel is available in single-dose vials of 30 mg/5 mLand 100 mg/16.7 mL for IV administration in the treatmentof breast, ovarian, NSCLC, and AIDS-related Kaposi sarcoma.Other uses have included treatment of head, neck,esophageal, cervical, prostate, and bladder cancers.
    Paclitaxel is highly plasma protein bound (>90%) anddoes not penetrate the CNS. Metabolism involves CYPmediatedoxidation to give 6 -hydroxypaclitaxel (CYP2C8)and para hydroxylation of the phenyl group attached to the3'-position (CYP3A4). The 6α-hydroxy metabolite normallypredominates, but the para hydroxy metabolite mayoccur to a greater degree in those patients with liver diseaseor when CYP3A4 has been induced. Both metabolites areless active than the parent and do not undergo phase II conjugationreactions. Elimination occurs primarily in the feces,and the elimination half-life is 9 to 50 hours depending onthe infusion period.
    The major toxicity seen with paclitaxel is a dose-limitingmyelosuppression that normally presents as neutropenia. Thepreviously mentioned hypersensitivity reactions occur but aregreatly reduced by antihistamine pretreatment. Interactionwith the axonal microtubules such as that seen for the vincasalso occurs and leads to numbness and paresthesias (abnormaltouch sensations including burning and prickling). Theagent is also available as an albumin-bound formulation(Abraxane) to eliminate the need for the solubilizing agentsassociated with the hypersensitivity reactions. Other adverseeffects include bradycardia, which may progress to heartblock, alopecia, mucositis, and/or diarrhea. Paclitaxel producesmoderate nausea and vomiting that is short-lived.
  • 一般的な説明 Needles (from aqueous methanol) or fine white powder. An anti-cancer drug.
  • 空気と水の反応 May be sensitive to prolonged exposure to moisture. .
  • 健康ハザード TOXIC; inhalation, ingestion or skin contact with material may cause severe injury or death. Contact with molten substance may cause severe burns to skin and eyes. Avoid any skin contact. Effects of contact or inhalation may be delayed. Fire may produce irritating, corrosive and/or toxic gases. Runoff from fire control or dilution water may be corrosive and/or toxic and cause pollution.
  • 火災危険 Flash point data for Paclitaxel are not available. Paclitaxel is probably combustible.
  • 生物活性 Antitumor agent; promotes and stabilizes tubulin polymerization, causing cell cycle arrest. Induces autocatalytic activation of caspase-10 in CCRF-HSB-2 cells, triggering apoptosis.
  • 作用機序 Paclitaxel’s large volume of distribution indicates significant tissue binding. The drug is extensively metabolized by the liver, and doses must be reduced in patients with abnormal liver function or with extensive liver metastases.Very little of the drug is excreted in the urine.
  • 臨床応用 Paclitaxel is among the most active of all anticancer drugs, with significant efficacy against carcinomas of the breast, ovary, lung, head, and neck. It is combined with cisplatin in the therapy of ovarian and lung carcinomas and with doxorubicin in treating breast cancer.
  • 抗がん研究 It is isolated from the bark of Taxus brevifolia generally known as pacific yew. It isprimarily used in ovarian, small, and non-small cell lung cancers and advancedbreast cancer (Shoeb 2006). It binds to tubulin but neither depolymerizes it nor interferes with its assembly (Balunas and Kinghorn 2005). Taxol targets activatorprotein 1 signaling pathways (Singh et al. 2016b).
  • 抗がん研究 Paclitaxel (commercial name, Taxol) a complex diterpene alkaloid isnaturally obtained from Taxus species (family Taxaceae). Paclitaxel has been provedas highly effective in the treatment of various types of cancers, since it acts as amicrotubule-stabilizing agent to protect against disassembly. Paclitaxel was developed by the National Cancer Institute, USA, as a drug for cancer therapy andused for the treatment of refractory ovarian cancer, metastatic breast and lung cancer,and Kaposi’s sarcoma (Srivastava et al. 2005). The natural source of paclitaxelis the bark of several Taxus species; however, the cost of extraction is very highsince the concentration of paclitaxel accumulation is very low (0.02% of dry weight)and also entails the destruction of natural resources (Cusido et al. 2014). Eventhough, paclitaxel can be chemically synthesized, but this process is not commerciallyviable. Plant cell cultures have been developed for the production of paclitaxelby Phyton Biotech in 1995, and in 2004 the FDA has approved the use of plantculture supply of paclitaxel/Taxol (Leone and Roberts 2013).
  • 副作用 Myelosuppression is the major side effect of paclitaxel. Alopecia is common, as is reversible dose-related peripheral neuropathy. Most patients have mild numbness and tingling of the fingers and toes beginning a few days after treatment. Mild muscle and joint aching also may begin 2 or 3 days after initiation of therapy. Nausea is usually mild or absent. Severe hypersensitivity reactions may occur. Cardiovascular side effects, consisting of mild hypotension and bradycardia, have been noted in up to 25% of patients.
  • 代謝 The major use-limiting adverse effect of paclitaxel is dose-dependent myelosuppression, particularly neutropenia, and first doses may need to be decreased in patients with hepatic dysfunction. Subsequent dose reductions, if any, should be tailored to individual response. The drug should not be given to patients who have baseline neutrophil counts below 1,500 cells/mm3. The albumin-bound formulation also is associated with sensory neuropathy.
パクリタキセル 上流と下流の製品情報
パクリタキセル 生産企業
  • 名前:Jiangsu Yew Pharmaceutical Co., Ltd.
  • 電話番号:+86-510-66865338 +86-189-2133-5032
  • ファックス番号:+86-510-66865972
  • 電子メール ;
  • 国籍:CHINA
  • 製品カタログ:30
  • 優位度:60
  • 名前:Beijing Yibai Biotechnology Co., Ltd
  • 電話番号:0086-182-6772-3597
  • ファックス番号:
  • 電子メール
  • 国籍:CHINA
  • 製品カタログ:420
  • 優位度:58
  • 名前:Frapp's ChemicalNFTZ Co., Ltd.
  • 電話番号:+86 (576) 8169-6106
  • ファックス番号:+86 (576) 8169-6105
  • 電子メール
  • 国籍:China
  • 製品カタログ:886
  • 優位度:50
  • 名前:Henan Tianfu Chemical Co.,Ltd.
  • 電話番号:0371-55170693
  • ファックス番号:0371-55170693
  • 電子メール
  • 国籍:CHINA
  • 製品カタログ:22607
  • 優位度:55
  • 名前:Hangzhou FandaChem Co.,Ltd.
  • 電話番号:008615858145714
  • ファックス番号:+86-571-56059825
  • 電子メール
  • 国籍:CHINA
  • 製品カタログ:8875
  • 優位度:55
  • 電話番号:18371201331
  • ファックス番号:020-81716319
  • 電子メール
  • 国籍:CHINA
  • 製品カタログ:3077
  • 優位度:55
  • 名前:Nanjing Finetech Chemical Co., Ltd.
  • 電話番号:025-85710122 17714198479
  • ファックス番号:025-85710122
  • 電子メール
  • 国籍:CHINA
  • 製品カタログ:890
  • 優位度:55
  • 電話番号:+86 21 5161 9050/ 5187 7795
  • ファックス番号:+86 21 5161 9052/ 5187 7796
  • 電子メール
  • 国籍:CHINA
  • 製品カタログ:26711
  • 優位度:60
33069-62-4, パクリタキセル キーワード:
  • 33069-62-4
  • Paclitaxel HCL
  • Paclitaxel(natural crude)
  • Paclitaxelx
  • taxol a
  • TAXOL(R)
  • taxal
  • αR-hydroxy-βS-(benzoylamino)-benzenepropanoic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester
  • Paclitaxel, Antibiotic for Culture Media Use Only
  • 7,11-methano-5h-cyclodeca[3,4]benz[1,2-b]oxete benzenepropanoic acid deriv.
  • [2ar-[2aalpha,4beta,4abeta,6beta,9alpha(alphar*,betas*),11alpha,12alpha,12bal
  • Paclitaxel from Taxus Mairei
  • 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-ylester, (αR, βS)-
  • Benzenepropanoicacid, β-(benzoylamino)- α
  • -hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-
  • Yewtaxan
  • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenyli
  • Paclitaxel/Taxal
  • [2aR-[2aα,4β,4aβ,6α,9α(αR*,βS*),11α,12α,12aα,12bα]]-β-(Benzoylamino)-α-hydroxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-ylesterbenzenepropanoicacid
  • Paclitaxel (200 mg)
  • Paclitaxel(Natural/Semi-Synthetic)
  • パクリタキセル
  • タキソール
  • パクリタキセル (JAN)
  • 生化学
  • 試験研究用抗腫瘍剤
  • ジテルペン
  • テルペン